Actively Recruiting
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Led by Assiut University · Updated on 2024-07-30
150
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
CONDITIONS
Official Title
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with hepatocellular carcinoma
- Not previously treated with systemic tyrosine kinase inhibitors (TKIs)
You will not qualify if you...
- Presence of liver tumors other than hepatocellular carcinoma
- Child-Pugh grade C liver function
- Other malignancies
- Chronic inflammatory disorders
- Severe organ dysfunction (heart, lung, kidney)
- Allergy or intolerance to sorafenib
- Severe uncorrectable coagulation problems
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NLI
Shibīn al Kawm, Menoufia, Egypt, 32511
Actively Recruiting
Research Team
M
Mahmoud Nazih
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here